Skip to content

Opsys bulking agent bij mannelijke incontinentie

INJECTABLE BULKING AGENT FOR MALE URINARY INCONTINENCE TREATMENT: A MULTI-CENTRE PILOT SAFETY AND EFFICACY STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON26801
Enrollment
Unknown
Registered
2016-07-25
Start date
2016-06-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mannelijk incontinentie bulking stof male incontinence bulking agent

Interventions

Opsys will be implanted in urethra using a video endoscope with a transurethral injection needle. All the procedures will be recorded on CD-Rom.

Sponsors

Not sponsored trial performer ZGT and Jeroen Bosch Ziekenhuis
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Subject remains dry at night. • Ability to voluntarily stop micturition. • Stress Urinary Incontinence caused by Intrinsic sphincter deficiency ISD secondary to a post RP, refractory to conservative treatment with a post-operative of at least 12 months. • Urinary incontinence classified as mild incontinence level by a 24 h pad weight test mentioned in the clinical data (less than 30 g per day urine loss on 24 h pad weight test), and quality of life has deteriorated so as to require surgery as a method of treatment. • Consent informed signed. Subjects will be physical and urodynamically examined to confirm RP SUI. The degree of urine leakage will be quantified using two 24 h pad weight test

Exclusion criteria

Exclusion criteria: • Post-prostatectomy radiotherapy or brachytherapy. • Subject radiated as treatment of Prostate Cancer, being this interstitial or external, neo-adjuvant, therapeutic or adjuvant. • Bladder neck sclerosis or urethral stricture. • Urge Incontinence

Design outcomes

Primary

MeasureTime frame
The main study endpoint is whether treatment was successful, based on the two 24 h pad weight test (PWT) before and after treatment. The success rate of the procedure will be assessed according to the following criteria presented in Table 2. Table 2. Criteria for defining treatment success, improvement and failure. ResultCriteria EndpointActual valueEndpointActual value SUCCESS24-h PWT0 -3 gORVoiding diary (Count pads)0 pads IMPROVEMENT24-h PWT¡Ý 50% reductionORVoiding diary (Count pads)¡Ý 50% less usage of pads FAILUREUnable to meet the previous criteria

Secondary

MeasureTime frame
Secondary endpoints are: • 48 h voiding diary to record micturition episodes • Complete Urinalysis with Urine culture • Urodynamic evaluation: o Uroflowmetry o Urethral pressure (leak point pressure measurement before and after surgery) o Cystometric test o Post Void Residual Measurement • International Consultation on Incontinence Questionnaire ¨C Short Form (ICIQ-UI-SF) • Incontinence Impact Questionnaire ¨C Short Form (IIQ-7) • Patient Global Impression of Improvement (PGI-I) • Urogenital Distress Inventory (UDI-6) Safety endpoints are: • Record of intraoperative complications (including device and surgical instrument (needle) complications and procedure related problems). • Record of postoperative complications (e.g. urinary retention, voiding pain, etc.). • Visual Analogue Scale for assessment of pain (pre- and postoperative). • Any other adverse events regarding safety issues will be recorded and followed-up after their appearance.

Contacts

Public ContactE.B. Cornel

Ziekenhuis groep Twente

e.cornel@zgt.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)